Recognition of impaired atomoxetine metabolism because of low CYP2D6 Activity

Pediatric Neurology

Volumn 43, Issue 3, 2010, Pages 159-162

  Ter Laak, Maureen A ^a   Temmink, Alphons H ^a   Koeken, Ankie ^a   Van 'T Veer, Nils E ^a   Van Hattum, Paul R M ^a   Cobbaert, Christa M ^a  

^a AMPHIA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; AWARENESS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; HUMAN; MALAISE; MALE; MENTAL INSTABILITY; METABOLIC DISORDER; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCHOOL CHILD; SLEEP DISORDER; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; PHARMACOGENETICS; PROPYLAMINES; RETROSPECTIVE STUDIES;

EID: 77955530358     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2010.04.004     Document Type: Article

References (7)

1. B. Ring, J. Gillespie, J. Eckstein, and S. Wrighton Identification of the human cytochromes P450 responsible for atomoxetine metabolism Drug Metab Dispos 30 2002 319 323
2. G-Standaard Farmacogenetica. Algemene achtergrondtekst Farmacogenetica - CYP2D6. Available at: http://www.kennisbank.knmp.nl/index.asp
3. W. Steimer, K. Zöpf, and S. von Amelunxen Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers Clin Chem 50 2004 1623 1633
4. J. de Leon, M. Susce, and E. Murray-Carmichael The AmpliChip™ CYP450 genotyping test. Integrating a new clinical tool Mol Diagn Ther 10 2006 135 151
5. 610 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers Biol Pharm Bull 28 2005 1476 1479
6. D. Michelson, H.A. Read, D.D. Ruff, J. Witcher, S. Zhang, and J. McCracken CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD J Am Acad Child Adolesc Psychiatry 46 2007 242 251
7. P.T. Trzepacz, D.W. Williams, P.F. Feldman, R.E. Wrishko, J.W. Witcher, and J.K. Buitelaar CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD Eur Neuropsychopharmacol 18 2008 79 86